Search Within

Ghassan Abou-Alfa

Formats
  1. Meeting Abstract (262)
  2. Journal Article (244)
  3. Review (25)
  4. Book Section (16)
  5. Editorial (8)
  6. Book Whole (4)
  7. Correspondence (4)
  8. Guidelines (4)
  9. Miscellaneous (3)
  10. Research Letter (1)
Groups
  1. Department of Medicine (571)
  2. Gastrointestinal Oncology Service (571)
  3. Solid Tumor Oncology Division (571)
  4. Center for Pancreatic Cancer Research (215)
  5. Epidemiology and Biostatistics (122)
  6. Surgery (103)

More Groups

People
  1. Eileen O'Reilly (156)
  2. James Harding (130)
  3. William Jarnagin (66)
  4. Marinela Capanu (65)
  5. Leonard Saltz (55)
  6. Imane El Dika (54)

More People

Years
  1. 2025 (16)
  2. 2024 (52)
  3. 2023 (48)
  4. 2022 (53)
  5. 2021 (46)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (166)
  2. Annals of Oncology (53)
  3. Gastrointestinal Cancer Research (21)
  4. Oncology Research and Treatment (18)
  5. Annals of Surgical Oncology (15)
  6. Cancer (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (182)
  2. Oxford University Press (65)
  3. Springer (36)
  4. Wiley Blackwell (30)
  5. Elsevier Inc. (25)
  6. Elsevier Science, Inc. (22)

More Publishers

Results (571)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Metastatic well differentiated serotonin-producing pancreatic neuroendocrine tumor with carcinoid heart disease: A case report
    Journal Article

    Kudelka, M. R.; Abou-Alfa, G. K.; O’Reilly, E. M.; Foote, M. B.; Sirohi, B.; Elias, R.; Shamseddine, A.; Paroder, V.; Moussa, A. M.; Cohen, P.; more...
    Journal of Gastrointestinal Oncology (2023)

    Fulltext@MSK | Save
  • Health diplomacy in action: The cancer legacy of the Good Friday Agreement
    Editorial

    Lawler, M.; Sullivan, R.; Abou-Alfa, G. K.; McCloskey, K.; Keatley, D.; Feighan, J.; Dahut, W.; Mulroe, E.; Ladner, R.; Genead, M.; more...
    Journal of Cancer Policy (2023)

    Fulltext@MSK | Save
  • Concordance in oncogenic alterations between primary and recurrent/metastatic cholangiocarcinoma pairs using targeted next-generation sequencing
    Meeting Abstract

    McIntyre, S. M.; Preston, W.; Walch, H.; Sigel, C.; Sharib, J.; Chen, W.; Lidsky, M. E.; Kundra, R.; Cercek, A.; Harding, J. J.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage
    Meeting Abstract

    Sharib, J.; Liu, A.; McIntyre, S.; Rhodin, K. E.; Kemeny, N. E.; Cercek, A.; Harding, J. J.; Abou-Alfa, G. K.; Soares, K. C.; Wei, A. C.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Genetic heterogeneity of intrahepatic cholangiocarcinoma: Implications for outcome
    Meeting Abstract

    Song, Y.; Boerner, T.; Drill, E.; Shin, P.; Cercek, A.; Kemeny, N. E.; Abou-Alfa, G. K.; Iacobuzio-Donahue, C.; Schultz, N.; Walch, H.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
    Meeting Abstract

    Bullock, A.; Fakih, M.; Gordon, M.; Tsimberidou, A.; El-Khoueiry, A.; Wilky, B.; Pimentel, A.; Margolin, K.; Mahadevan, D.; Balmanoukian, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Meeting Abstract

    Sangro, B.; Chan, S.; Kelley, R.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E.; Furuse, J.; Kang, Y.; Galle, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Meeting Abstract

    Cowzer, D.; Capanu, M.; Keane, F.; Khalil, D.; Shia, J.; Do, R.; Chou, J.; Walch, H.; El Dika, I.; Yaqubie, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial
    Meeting Abstract

    Valle, J.; Abou-Alfa, G.; Kelley, R.; Lowery, M.; Shroff, R.; Bian, Y.; Saint-Hilary, G.; Liu, H.; Teng, Z.; Hua, Z.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy
    Meeting Abstract

    Keane, F.; Cowzer, D.; Khalil, D.; Shia, J.; Do, R.; Folorunso, S.; El Dika, I.; Yaqubie, A.; Kim, T.; O'Reilly, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save